HomeCompareITTGF vs ABBV

ITTGF vs ABBV: Dividend Comparison 2026

ITTGF yields 4450.38% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ITTGF wins by $20115833995536.76M in total portfolio value
10 years
ITTGF
ITTGF
● Live price
4450.38%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20115833995536.86M
Annual income
$19,264,314,850,364,195,000.00
Full ITTGF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ITTGF vs ABBV

📍 ITTGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodITTGFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ITTGF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ITTGF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ITTGF
Annual income on $10K today (after 15% tax)
$378,282.15/yr
After 10yr DRIP, annual income (after tax)
$16,374,667,622,809,565,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ITTGF beats the other by $16,374,667,622,809,545,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ITTGF + ABBV for your $10,000?

ITTGF: 50%ABBV: 50%
100% ABBV50/50100% ITTGF
Portfolio after 10yr
$10057916997768.48M
Annual income
$9,632,157,425,182,110,000.00/yr
Blended yield
95.77%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ITTGF
No analyst data
Altman Z
-12.9
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ITTGF buys
0
ABBV buys
0
No recent congressional trades found for ITTGF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricITTGFABBV
Forward yield4450.38%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20115833995536.86M$102.3K
Annual income after 10y$19,264,314,850,364,195,000.00$24,771.77
Total dividends collected$20057987584971.55M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ITTGF vs ABBV ($10,000, DRIP)

YearITTGF PortfolioITTGF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$455,738$445,037.83$11,550$430.00+$444.2KITTGF
2$19,442,833$18,955,193.77$13,472$627.96+$19.43MITTGF
3$776,572,570$755,768,737.95$15,906$926.08+$776.56MITTGF
4$29,042,527,654$28,211,595,004.54$19,071$1,382.55+$29042.51MITTGF
5$1,017,119,353,853$986,043,849,263.12$23,302$2,095.81+$1017119.33MITTGF
6$33,362,106,857,818$32,273,789,149,195.72$29,150$3,237.93+$33362106.83MITTGF
7$1,025,042,379,787,030$989,344,925,449,164.80$37,536$5,121.41+$1025042379.75MITTGF
8$29,505,557,136,899,050$28,408,761,790,526,924.00$50,079$8,338.38+$29505557136.85MITTGF
9$795,812,285,208,096,900$764,241,339,071,615,000.00$69,753$14,065.80+$795812285208.03MITTGF
10$20,115,833,995,536,860,000$19,264,314,850,364,195,000.00$102,337$24,771.77+$20115833995536.76MITTGF

ITTGF vs ABBV: Complete Analysis 2026

ITTGFStock

Intact Gold Corp. engages in the acquisition, exploration, and evaluation of mineral properties in Canada. The company holds interests in the Gold Hill-Blackjack property situated in the Kenora mining division of Ontario; the Belle Terre property located in Quebec; and the Little Phoenix property consisting of 2 claims covering an area of 2,362 hectares located in British Columbia. The company was formerly known as First Americas Gold Corporation and changed its name to Intact Gold Corp. in February 2016. Intact Gold Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.

Full ITTGF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ITTGF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ITTGF vs SCHDITTGF vs JEPIITTGF vs OITTGF vs KOITTGF vs MAINITTGF vs JNJITTGF vs MRKITTGF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.